-
Mashup Score: 0
Using two-dimensional X-rays in a 3D surgery setting has always been unwieldy. But, in the future, GE Healthcare hopes to make visualizing them a bit easier. | The upcoming OmnifyXR system will be designed to provide a heads-up display of interventional X-ray imaging using Microsoft’s HoloLens hardware.
Source: Fierce BiotechCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 22
Multiple myeloma is still an uncurable cancer, but Johnson & Johnson’s Janssen unit is building a toolkit to fight back. | Multiple myeloma is still an uncurable cancer, but Johnson & Johnson’s Janssen unit is building a toolkit to fight back. The latest additions are the bispecific antibodies teclistamab and talquetamab, both being tested in heavily pretreated patients. Janssen will showcase…
Source: Fierce BiotechCategories: Hem/Oncs, Latest HeadlinesTweet-
#ASCO22 J&J's multiple myeloma toolkit expands with impressive data on bispecific antibodies: teclistamab (BCMA/CD3) combined with daratumumab (CD38) showing 78% ORR; and single drug talquetamab (GPRC5D/CD3) showing 65-70% ORR. Great for patients! #mmsm https://t.co/TIKWmctVPs
-
-
Mashup Score: 0Roche rolls out trio of PCR research tests for monkeypox - 2 year(s) ago
If there’s one positive outcome of the COVID-19 pandemic, it’s the speed at which diagnostic test makers learned to develop and begin churning out kits to test for a virus. | If there’s one positive outcome of the COVID-19 pandemic, it’s the speed at which diagnostic test makers learned to develop and begin churning out kits to test for a virus.
Source: Fierce BiotechCategories: Healthcare Professionals, Latest HeadlinesTweet-
.@Roche rolls out trio of #PCR research tests for #monkeypox | #diagnostics https://t.co/ZgVqLanbgh
-
-
Mashup Score: 0With failed COVID shot still dragging on earnings, CureVac tries to turn page to next-gen mRNA tech - 2 year(s) ago
CureVac’s first-generation COVID vaccine—a shot that failed to reach anywhere near the
Source: Fierce BiotechCategories: Infectious Disease, Latest HeadlinesTweet-
“shown an improved side effect profile compared to first-generation mRNA shots in preliminary data from an influenza trial, CureVac said. The updated mRNA tech also improved intracellular mRNA translation for increased and extended protein expression” https://t.co/JW0eK40FA1
-
-
Mashup Score: 0Novel cancer vaccines by Dana-Farber and Stanford look beyond T cells to better fight tumors - 2 year(s) ago
Most cancer immunotherapies primarily rely on T cells to neutralize tumors. | Most cancer immunotherapies primarily rely on T cells to neutralize tumors. But in two new studies, scientists at Dana-Farber Cancer Institute and Stanford University have described novel immuno-oncology approaches, showing that mobilizing B cells and NK cells may achieve better antitumor effects.
Source: Fierce BiotechCategories: Healthcare Professionals, Latest HeadlinesTweet-
https://t.co/f4KOQp1vhc
-
-
Mashup Score: 1FDA clears NeuroMetrix's wearable neuromodulator as first non-drug fibromyalgia treatment - 2 year(s) ago
Scientists still may not know the exact cause of fibromyalgia, but that hasn’t stopped them from developing treatments for the chronic pain associated with the condition. | With the FDA’s nod, Massachusetts-based NeuroMetrix plans to launch the wearable, prescription-only Quell system as a fibromyalgia treatment in the fourth quarter of this year.
Source: Fierce BiotechCategories: Healthcare Professionals, Latest HeadlinesTweet-
#FDA clears NeuroMetrix's #wearables @Quellrelief neuromodulator as first non-drug #fibromyalgia treatment | #neuromodulation https://t.co/kgIyb5V5Mm
-
-
Mashup Score: 0Fractyl shows its intestine-resurfacing device for Type 2 diabetes improves insulin resistance, pancreatic function - 2 year(s) ago
Fractyl Health posted new data from its device-based, one-time diabetes treatment, showing its approach not only helped lower average blood sugar but also led to improvements in long-term insulin r | The Revita DMR outpatient procedure strips out and helps reset the small intestine’s lining, which can thicken over years from dietary fats, sugars and other foods.
Source: Fierce BiotechCategories: Healthcare Professionals, Latest HeadlinesTweet-
.@FractylHealth shows its intestine-resurfacing device for #Type2 #diabetes improves insulin resistance, pancreatic function https://t.co/xT7aTAwyYW
-
-
Mashup Score: 2
AstraZeneca and BenevolentAI have notched another achievement in their artificial-intelligence-powered drug discovery collaboration. | After securing targets in chronic kidney disease and idiopathic pulmonary fibrosis (IPF), AstraZeneca is collecting a second IPF target from its recently reupped collaboration with BenevolentAI.
Source: Fierce BiotechCategories: Healthcare Professionals, Latest HeadlinesTweet-
.@AstraZeneca collects 2nd #pulmonaryfibrosis target from @benevolent_ai #AI #drugdiscovery collaboration https://t.co/lwvscUn5TM
-
-
Mashup Score: 3'We just don’t have the studies': New report details critical diversity shortcomings in US clinical research - 2 year(s) ago
“We just don’t have the studies” became a familiar refrain for Kirsten Bibbins-Domingo, M.D., Ph.D., chair of the Committee on Improving Representation of Women and Underrepresented Minorities in C | “We just don’t have the studies” became a familiar refrain for Kirsten Bibbins-Domingo, M.D., Ph.D., chair of the Committee on Improving Representation of Women and Underrepresented Minorities in…
Source: Fierce BiotechCategories: Healthcare Professionals, Latest HeadlinesTweet-
Thank you @AGKootenay @FierceBiotech for the outstanding coverage of our new @theNASEM report on clinical trials We just don’t have the studies': New report details critical diversity shortcomings in US clinical research https://t.co/3sBWKTUyuo
-
-
Mashup Score: 0
In a major boon for the battle against breast cancer—which recently overtook lung cancer as the world’s most common form of cancer—artificial intelligence technologies designed to automatically det | To make MammoScreen more ubiquitous in cancer screening across the U.S., Therapixel plans to add new features and ramp up its sales and commercial activities in the region.
Source: Fierce BiotechCategories: Healthcare Professionals, Latest HeadlinesTweet-
Mammogram-reading AI developer @therapixel snags €15M to expand US presence | #Radiology #AI https://t.co/clNh4mGsQl
-
.@GEHealthcare looks to bring @MediViewXR #AR headsets to X-ray-guided surgeries | #digitalsurgery #Augmentedreality #surigcalnavigaion https://t.co/S1pmnabImX